Overall, BRAF mutations in NSCLC show an intermediate frequency between EGFR mutations and ROS1 rearrangements, similar to ALK rearrangement [25], and deserve special attention for the possible use of targeted therapy. The gene discussed is ALK; the disease is non-small cell lung carcinoma.